Eloxx Pharmaceuticals CEO to speak at Guggenheim Healthcare Innovation Conference

Eloxx Pharmaceuticals CEO Sumit Aggarwal will address the 3rd Annual Guggenheim Healthcare Innovation Conference on November 9, 2026. The event serves as a platform for clinical-stage biopharmaceutical companies to provide updates on their research and development pipelines to stakeholders and investors.

The company is currently focused on the clinical development of its lead product candidate, exaluren, which aims to treat rare kidney diseases including nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD). Eloxx utilizes a technology platform designed to modulate the ribosome, potentially enabling the production of full-length proteins in cases involving nonsense mutations.

The presentation will be accessible via a live webcast on the company’s investor relations website, with a replay made available following the event.